Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Attorney General secures $35 Novo Nordisk insulin for Minnesotans
The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.
Latest pharma lawsuit settlement expands low-cost insulin to more Minnesotans
Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three ...
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
San Diego Reader6d
Newsom’s $100 million San Diego insulin give-away stalls
Newsom’s insulin fail. A drive by California Gov. Gavin Newsom to make low-cost insulin by spending $100 million in state ...